Habte Yimer, MD from Texas Oncology discusses Phase 2 study of Daratumumab and assess good, partial, or better response after 4 cycles at the 2017 American Society of Hematology.
Phase 2 Study of Daratumumab – Assess good, partial, or better response after 4 cycles
